Evidence map›Paper›PMID 30949839›Full record

ArticleInternational urology and nephrology2019

Which treatment is best for patients with AJCC stage IV bladder cancer?

WeiPu Mao, BingWei Ma, Xin Huang, SiMin Gu, Ming Luo, Jie Fan, Jiang Geng

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Research progress of MUC1 in genitourinary cancers.Cellular & molecular biology letters · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

WeiPu MaoDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, China.
BingWei MaDepartment of Gastrointestinal Surgery, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Xin HuangDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, China.
SiMin GuDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, China.
Ming LuoDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, China.
Jie FanDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China. fanfanj369@sina.com.
Jiang GengDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, China. gengjiangsn@sina.com.ORCID http://orcid.org/0000-0003-1722-3561

Funding

National Natural Science Foundation of China 81101803Tongji University 1501219143
6 · The paper itself

Abstract

purposeWe sought to identify the method that could obtain the best survival rate for AJCC stage IV bladder cancer (BCa) patients.

methodsPatients with AJCC stage IV BCa diagnosed between 2004 and 2015 were identified using the Surveillance, epidemiology and end results (SEER) database. Kaplan-Meier curves and log-rank test were used for overall survival (OS) and cancer-specific survival (CSS). Multivariable Cox regression was used to determine factors associated with all-cause mortality (ACM) and cancer-specific mortality (CSM).

resultsWe found that among the 11824 patients, the number of patients who received chemotherapy (CT), radiotherapy (RT) and radical cystectomy (RC) was 6243 (52.8%), 2005 (17.0%) and 4987 (42.2%), respectively. Patients who received CT or RC had improved OS (26.4% vs. 11.7%, p < 0.001 and 27.3% vs. 13.7%, p < 0.001, respectively), but patients who underwent RT alone had lower OS (14.4% vs. 20.5%, p < 0.001). Furthermore, CT combined with RC was associated with the lowest ACM (hazard ratio (HR) = 0.26, 95% CI 0.24-0.28, p < 0.001) and the lowest CSM (HR = 0.24, 95% CI 0.22-0.26, p < 0.001). Patients who only received RT had the highest ACM (HR = 0.84, 95% CI 0.77-0.92, p < 0.001) and the highest CSM (HR = 0.85, 95% CI 0.77-0.94, p = 0.002).

conclusionsWe concluded that CT combined with RC was the best method with the highest survival rate for patients with AJCC stage IV BCa and that CT combined with RC had more benefits in improving OS and CSS than did RT alone.

Indexed as

Carcinoma, Transitional CellCystectomyRadiotherapyUrinary Bladder NeoplasmsAntineoplastic AgentsChinaCombined Modality TherapyFemaleHumansMaleMiddle AgedNeoplasm StagingSEER ProgramSurvival AnalysisAntineoplastic AgentsBladder cancerChemotherapyRadical cystectomyRadiotherapySEER

Identifiers

PMID30949839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.